Ensysce Biosciences Receives $1.5m from the State of Texas Emerging Technology Fund

Ensysce Biosciences, Inc., a Houston, TX-based nanotechnology company focusing on the use of carbon nanotubes for therapeutics in the area of cancer treatment, has received a $1.5m funding from the State of Texas Emerging Technology Fund.

The funds will be used for the development of single walled carbon nanotube (SWCNT) therapeutics for the delivery of siRNA and, in particular, to attract scientists to Houston to work on this technology.

According to the company, carbon nanotubes provide a means to deliver unmodified, large active molecular agents through natural barriers within the body and specifically into cancer cells.

Dr. Kirkpatrick, CEO of Ensysce, explained that “The siRNA delivery into tumors by SWCNT and biological activity has now been demonstrated in our animal studies”

“We are now optimizing the pharmaceutical preparations to demonstrate the universal nature of these SWCNT carriers for siRNA and believe we will enter clinical trials in the next 12 to 18 months”, he added.

In order to improve its research collaborations at M.D. Anderson Cancer Center and Rice University, the company recently moved to the Biotechnology Commercialization Center in the Texas Medical Center.